CIK 1425738
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 97.05% | 31 |
| Life Sciences Tools & Services | 1.64% | 1 |
| Health Care Equipment & Supplies | 1.31% | 3 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding Corp | Health Care | 29.51% |
| 2 | KRYS | Krystal Biotech, Inc. | Health Care | 11.52% |
| 3 | STOK | Stoke Therapeutics, Inc. | Health Care | 8.98% |
| 4 | IMNM | Immunome Inc. | Health Care | 8.05% |
| 5 | NRIX | Nurix Therapeutics, Inc. | Health Care | 7.94% |
| 6 | ANNX | Annexon, Inc. | Health Care | 5.34% |
| 7 | ADCT | ADC Therapeutics SA | Health Care | 3.84% |
| 8 | RGNX | REGENXBIO Inc. | Health Care | 2.42% |
| 9 | STTK | Shattuck Labs, Inc. | Health Care | 2.36% |
| 10 | BEAM | Beam Therapeutics Inc. | Health Care | 1.95% |
35/35 names classified · sector 100.0% of weight · industry 100.0% · mkt cap 99.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 100.0% of the book is sector-classified (unclassified names shown, never dropped).
Only 1% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.8% of book weight (2/35 names) · unclassified 99.2%: SRRK, KRYS, STOK, IMNM, NRIX, ANNX, ADCT, RGNX, STTK, BEAM +23 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | SRRKSCHOLAR ROCK HLDG CORP | 9,066,621 | $446M | 29.5% | ADD 74% |
| 2 | KRYSKRYSTAL BIOTECH INC | 673,505 | $174M | 11.5% | HOLD |
| 3 | STOKSTOKE THERAPEUTICS INC | 4,164,120 | $136M | 9.0% | ADD 3% |
| 4 | IMNMIMMUNOME INC | 5,558,885 | $122M | 8.1% | TRIM −3% |
| 5 | NRIXNURIX THERAPEUTICS INC | 7,732,808 | $120M | 7.9% | TRIM −4% |
| 6 | ANNXANNEXON INC | 14,549,768 | $81M | 5.3% | ADD 45% |
| 7 | ADCTADC THERAPEUTICS SA | 15,470,502 | $58M | 3.8% | HOLD |
| 8 | RGNXREGENXBIO INC | 4,368,804 | $37M | 2.4% | HOLD |
| 9 | STTKSHATTUCK LABS INC | 5,539,724 | $36M | 2.4% | HOLD |
| 10 | BEAMBEAM THERAPEUTICS INC | 1,237,659 | $29M | 2.0% | TRIM −4% |
| 11 | NGNENEUROGENE INC | 1,459,599 | $29M | 1.9% | HOLD |
| 12 | COGTCOGENT BIOSCIENCES INC | 688,036 | $26M | 1.8% | TRIM −52% |
| 13 | ABSIABSCI CORPORATION | 8,253,316 | $25M | 1.6% | HOLD |
| 14 | IDYAIDEAYA BIOSCIENCES INC | 521,117 | $17M | 1.1% | TRIM −30% |
| 15 | ALXOALX ONCOLOGY HLDGS INC | 7,964,188 | $16M | 1.1% | ADD 144% |
| 16 | FATEFATE THERAPEUTICS INC | 12,872,946 | $15M | 1.0% | HOLD |
| 17 | XENEXENON PHARMACEUTICALS INC | 262,674 | $15M | 1.0% | ADD 96% |
| 18 | SLDBSOLID BIOSCIENCES INC | 2,011,895 | $14M | 1.0% | ADD 8% |
| 19 | NUVBNUVATION BIO INC | 3,153,256 | $14M | 0.9% | HOLD |
| 20 | ZYMEZYMEWORKS INC | 491,654 | $12M | 0.8% | HOLD |
| 21 | SLNSILENCE THERAPEUTICS PLC | 2,164,777 | $11M | 0.8% | HOLD |
| 22 | DBVTDBV TECHNOLOGIES S A | 491,340 | $10M | 0.7% | TRIM −11% |
| 23 | BMRNBIOMARIN PHARMACEUTICAL INC | 173,859 | $10M | 0.7% | NEW |
| 24 | CLDXCELLDEX THERAPEUTICS INC NEW | 261,508 | $8M | 0.5% | TRIM −8% |
| 25 | CBLLCERIBELL INC | 386,786 | $7M | 0.5% | TRIM −11% |
| 26 | LIVNLIVANOVA PLC | 108,354 | $7M | 0.5% | TRIM −8% |
| 27 | ESTAESTABLISHMENT LABS HLDGS INC | 103,464 | $6M | 0.4% | TRIM −8% |
| 28 | PRMEPRIME MEDICINE INC | 1,590,832 | $6M | 0.4% | NEW |
| 29 | ORICORIC PHARMACEUTICALS INC | 415,710 | $5M | 0.3% | TRIM −7% |
| 30 | EPRXEupraxia Pharmaceuticals Inc | 700,000 | $5M | 0.3% | NEW |
| 31 | ARDXARDELYX INC | 733,350 | $4M | 0.3% | NEW |
| 32 | IVVDINVIVYD INC | 2,648,659 | $3M | 0.2% | HOLD |
| 33 | ATRAATARA BIOTHERAPEUTICS INC | 441,701 | $2M | 0.1% | HOLD |
| 34 | AGMBAGOMAB THERAPEUTICS NV | 156,250 | $2M | 0.1% | NEW |
| 35 | PLRXPLIANT THERAPEUTICS INC | 772,126 | $972,879 | 0.1% | TRIM −52% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| SRRKSCHOLAR ROCK HLDG CORP | 4.5M | 4.4M | 3.9M | 3.9M | 5.2M | 9.1M | $446M |
| KRYSKRYSTAL BIOTECH INC | 753K | 738K | 663K | 661K | 678K | 674K | $174M |
| STOKSTOKE THERAPEUTICS INC | 4.6M | 4.5M | 4.4M | 4.2M | 4.0M | 4.2M | $136M |
| IMNMIMMUNOME INC | 4.8M | 5.4M | 4.9M | 5.0M | 5.7M | 5.6M | $122M |
| NRIXNURIX THERAPEUTICS INC | 4.2M | 4.1M | 3.7M | 3.7M | 8.1M | 7.7M | $120M |
| ANNXANNEXON INC | 6.3M | 6.3M | 6.3M | 6.3M | 10.1M | 14.5M | $81M |
| ADCTADC THERAPEUTICS SA | 15.7M | 15.7M | 15.7M | 15.7M | 15.7M | 15.5M | $58M |
| RGNXREGENXBIO INC | 4.8M | 4.8M | 4.8M | 4.7M | 4.4M | 4.4M | $37M |
| STTKSHATTUCK LABS INC | 5.5M | 5.5M | 5.5M | 5.5M | 5.5M | 5.5M | $36M |
| BEAMBEAM THERAPEUTICS INC | 1.5M | 1.6M | 1.4M | 1.4M | 1.3M | 1.2M | $29M |
| NGNENEUROGENE INC | 1.3M | 1.3M | 1.3M | 1.3M | 1.5M | 1.5M | $29M |
| COGTCOGENT BIOSCIENCES INC | 3.6M | 3.2M | 1.4M | 2.2M | 1.4M | 688K | $26M |
| ABSIABSCI CORPORATION | 8.3M | 8.3M | 8.3M | 8.3M | 8.3M | 8.3M | $25M |
| IDYAIDEAYA BIOSCIENCES INC | 619K | 535K | 432K | 742K | 742K | 521K | $17M |
| ALXOALX ONCOLOGY HLDGS INC | 3.7M | 3.6M | 3.4M | 3.3M | 3.3M | 8.0M | $16M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
